Remove Drug Pricing Remove Pharmaceutical Companies Remove Pharmaceutical Manufacturing
article thumbnail

Would the Industry Survive 200% Pharma Tariffs?

Pharma Marketing Network

Or would it unravel under the weight of economic retaliation, manufacturing disruptions, and rising drug prices? Table of Contents The Ripple Effects of Tariffs on Drug Pricing Manufacturing Dependencies and Global Disruption Impact on Pharma Marketing and Innovation Budgets Can the Industry Adapt or Will It Fracture?

article thumbnail

Changing the PAP Model

Pharmaceutical Commerce

Structuring patient assistance programs as independent non-profit foundations helps pharmaceutical companies reduce regulatory and legal exposure while allowing for more holistic, patient-centered support. Lastly, PAPs that are directly managed by pharmaceutical companies may also struggle with public image issues.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). The MHLW is currently proposing discussions on the FY2023 drug price revision.

article thumbnail

Pharmacy benefit management demystified: How PBMs influence prescription drug pricing

HealthPartners

Ultimately, this insight can help ensure your company and your employees are getting the greatest value from your pharmacy benefits plan. Understanding pharmacy benefit management and drug pricing The U.S. prescription drug supply chain is extraordinarily complex. To better understand it, see the below diagram.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). The MHLW is currently proposing discussions on the FY2023 drug price revision.

article thumbnail

Bolstering Health Technology Assessment With the Help of AI

Pharmaceutical Commerce

AI in value-based pricing and RWE generation AI has the potential to transform value-based pricing (VBP) by leveraging machine learning for dynamic pricing models that adjust drug prices based on real-world patient outcomes.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 5) monitoring access to biosimilars.